Lead-In Treatment to Reduce Tumor Lysis Syndrome Risk in CLL
Kerry Rogers, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discusses a short-term treatment strategy for reducing tumor burden and the risk for tumor lysis syndrome in patients with chronic lymphocytic leukemia.
Kerry Rogers, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discusses a short-term treatment strategy for reducing tumor burden and the risk for tumor lysis syndrome in patients with chronic lymphocytic leukemia (CLL).
This was an analysis of a phase Ib/II study that included brief treatment with obinutuzumab (Gazyva) and ibrutinib (Imbruvica) prior to venetoclax (Venclexta). After 1 month of obinutuzumab, patients had dramatically reduced lymphocyte count. Lymphocytosis wasseen with the addition of ibrutinib, however, the lymphocyte count was nowhere near what it was prior to the patient receiving obinutuzumab, Rogers explains.
